Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)
READ ARTICLE
READ ARTICLE
Precision Biologics, Inc. publishes paper on latest findings of the unique target that NEO-201 recognizes,...
BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present...
Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...
Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...
Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
Dr. Joyson Karakunnel joins the Board of Directors of Precision Biologics, Inc. as its newest...